Healthy Volunteers Clinical Trial
Official title:
Thyroid Hormones Homeostasis and Energy Metabolism Changes During Stimulation of Endogenously Secreted Bile Acids (BAs)
Postprandial thermogenesis, or thermic effect of food are terms that describe the increase in
utilization of energy by the human body following a meal. The mechanisms involved in this
process are believed to differ according to the type of food consumed, whether fat, protein
or carbohydrate.
The bile acids (BAs), unique substances secreted by the gall bladder into the gut after a
meal, play an important role in the absorption of fat and the management of cholesterol
stores in the body. Recent studies suggest that BAs may also serve as regulators of energy
expenditure (consumption) in the cells of our body by increasing the production of T3, an
active form of thyroid hormone. T3 in turn is believed to increase the efficiency with which
our bodies burn calories thereby generating heat. Although this process has been shown to be
effective in rodents who demonstrated weight loss after treatment, the role of BAs in humans
is poorly understood. Thus we do not know whether endogenous (produced by the body) or
exogenous (taken as medication) BAs play a significant role in the maintenance of body
weight. We hypothesize that, similarly to rodents, humans will respond to BAs by increasing
energy expenditure via the production of the active form of thyroid hormone.
This randomized, cross-over study will look at changes in thyroid hormones and energy
consumption in response to stimuli of endogenous BA secretion including dietary content, and
to the intake of pharmacological doses of bile acids.
Following a two-day period of equilibration diet, 30 healthy volunteers will be randomly
assigned to receive either a high-fat or high-carbohydrate isocaloric meal followed by a
6-hour metabolic chamber stay; the next day they will be crossed-over to the alternate
intervention. During the following three days, the study subjects will again be randomized to
receive either an intravenous injection of sincalide (the C-terminal octapeptide fragment of
cholecystokinin) 0.04 mcg/kg or placebo and P.O. placebo, or I.V. placebo and 15 mg/kg of BA
(ursodiol) with similar metabolic chamber stays and cross-over design.
The data gathered from this study will provide greater insight into the physiological and
molecular mechanism(s) regulating the relation between endogenous bile acid secretion and
energy metabolism in response to meals, as well as the role of BAs per se on energy
metabolism.
Postprandial thermogenesis, or thermic effect of food are terms that describe the increase in
utilization of energy by the human body following a meal. The mechanisms involved in this
process are believed to differ according to the type of food consumed, whether fat, protein
or carbohydrate.
The bile acids (BAs), unique substances secreted by the gall bladder into the gut after a
meal, play an important role in the absorption of fat and the management of cholesterol
stores in the body. Recent studies suggest that BAs may also serve as regulators of energy
expenditure (consumption) in the cells of our body by increasing the production of T3, an
active form of thyroid hormone. T3 in turn is believed to increase the efficiency with which
our bodies burn calories thereby generating heat. Although this process has been shown to be
effective in rodents who demonstrated weight loss after treatment, the role of BAs in humans
is poorly understood. Thus we do not know whether endogenous (produced by the body) or
exogenous (taken as medication) BAs play a significant role in the maintenance of body
weight. We hypothesize that, similarly to rodents, humans will respond to BAs by increasing
energy expenditure via the production of the active form of thyroid hormone.
This randomized, cross-over study will look at changes in thyroid hormones and energy
consumption in response to stimuli of endogenous BA secretion including dietary content, and
to the intake of pharmacological doses of bile acids.
Following a two-day period of equilibration diet, 30 healthy volunteers will be randomly
assigned to receive either a high-fat or high-carbohydrate isocaloric meal followed by a
6-hour metabolic chamber stay; the next day they will be crossed-over to the alternate
intervention. During the following three days, the study subjects will again be randomized to
receive either an intravenous injection of sincalide (the C-terminal octapeptide fragment of
cholecystokinin) 0.04 mcg/kg or placebo and P.O. placebo, or I.V. placebo and 15 mg/kg of BA
(ursodiol) with similar metabolic chamber stays and cross-over design.
The following parameters will be recorded and compared to placebo:
Energy expenditure
Substrate utilization
Spontaneous movements
Skin and core temperature
Serial changes in circulating thyroid hormones
Serial changes in bile acid serum concentrations
The data gathered from this study will provide greater insight into the physiological and
molecular mechanism(s) regulating the relation between endogenous bile acid secretion and
energy metabolism in response to meals, as well as the role of BAs per se on energy
metabolism.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
| Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
| Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
| Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
| Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
| Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
| Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
| Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
| Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
| Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
| Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
| Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
| Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
| Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
| Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
| Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
| Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |